BioLineRx Ltd. (NASDAQ:BLRX) headquartered in Modiin, will host a conference call for the investment community to discuss the 3Q20 earnings result on 23rd November 2020 at 10:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.biolinerx.com
Individuals interested in participating in the audio call may dial the listen only number(s) +1-866-744-5399 (United States) or +972-3-918-0664 Toll Number
Earnings Expectation
BioLineRx Ltd. is set to announce third quarter earning results on Monday 23rd November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BLRX to report 3Q20 loss of $ 0.35 per share. For the full year, analysts anticipate loss of $ 1.66 per share bottom line.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc.
